NCT07520175
A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle Glaucoma
Enrolling by Invitation
Not specifiedAll AgesObservationalIantrek, Inc.
~300 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:AlloSpan Canal Platform Bio-Reinforced Canaloplasty
At a glance
Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean change in IOP
Measured over 12 months, 24 months
Conditions
Where it's being run
7 sites across 5 statesCalifornia2
Texas2
Minnesota1
Oregon1
Pennsylvania1
Study leadership
- Tsontcho Ianchulev, MD, MPH · STUDY_CHAIR · Chief Medical Officer
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Mean change in IOP12 months, 24 months
Mean change in IOP as compared to baseline without increase in IOP-lowering medications or secondary IOP-lowering surgery